NAS:CORT (USA) Also trade in: Germany UK

Corcept Therapeutics Inc

$ 10.31 -0.17 (-1.62%)
Volume: 482,900 Avg Vol (1m): 859,657
Market Cap $: 1.18 Bil Enterprise Value $: 997.30 Mil
P/E (TTM): 16.92 P/B: 4.48
Earnings Power Value 3.45
Net Current Asset Value 1.47
Tangible Book 2.31
Projected FCF 5.19
Median P/S Value 55.97
Graham Number 5.63
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 10/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
96.66% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
CORT: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
Cash-To-Debt range over the past 10 years
Min: 0.72, Med: 643.08, Max: 10000
Current: 10000
0.72
10000
Equity-to-Asset 0.89
Equity-to-Asset ranked higher than
84.53% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
CORT: 0.89
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.1, Med: 0.66, Max: 0.89
Current: 0.89
-0.1
0.89
Interest Coverage No Debt
Interest Coverage ranked lower than
68.20% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
CORT: No Debt
Ranked among companies with meaningful Interest Coverage only.
Interest Coverage range over the past 10 years
Min: 4.99, Med: 5539.34, Max: 10000
Current: 10000
4.99
10000
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 23.71
DISTRESS
GREY
SAFE
Beneish M-Score -2.84
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 90.36%
WACC 10.08%

Profitability & Growth : 6/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % 33.84
Operating Margin ranked higher than
94.19% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
CORT: 33.84
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -69827.59, Med: -55.44, Max: 35.62
Current: 33.84
-69827.59
35.62
Net Margin % 29.50
Net Margin ranked higher than
97.35% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
CORT: 29.5
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -69537.93, Med: -65.47, Max: 81.11
Current: 29.5
-69537.93
81.11
ROE % 29.78
ROE ranked higher than
98.99% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
CORT: 29.78
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -356.04, Med: -94.12, Max: 111.15
Current: 29.78
-356.04
111.15
ROA % 26.30
ROA ranked higher than
99.17% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
CORT: 26.3
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -104.67, Med: -55.74, Max: 89.27
Current: 26.3
-104.67
89.27
ROC (Joel Greenblatt) % 4552.21
ROC (Joel Greenblatt) ranked higher than
99.23% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
CORT: 4552.21
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -370585.71, Med: -12961.31, Max: 15259.34
Current: 4552.21
-370585.71
15259.34
3-Year Total Revenue Growth Rate 71.00
3-Year Revenue Growth Rate ranked higher than
91.40% of 651 companies
in the Biotechnology industry.
Industry Max: 906.3, Med: 1.1, Min: -100
CORT: 61.6
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
3-Year Revenue Growth Rate range over the past 10 years
Min: 0, Med: -100, Max: 230.2
Current: 61.6
0
230.2

» CORT's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:CORT

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NYSE:CBM NAS:ALEC NAS:RUBY XKRX:006280 NAS:IOVA NAS:INVA NAS:SGMO SZSE:002030 NAS:ORTX NAS:TBPH SHSE:600645 SHSE:603718 ROCO:4147 NAS:EDIT NAS:AIMT XKRX:095700 NAS:APLS NYSE:MYOV NAS:ATRA NAS:ZLAB
Traded in other countries HTD.Germany 0I3Q.UK
Address 149 Commonwealth Drive, Menlo Park, CA, USA, 94025
Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

Ratios

Current vs industry vs history
PE Ratio (TTM) 16.92
PE Ratio ranked higher than
83.47% of 248 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.79, Min: 0.01
CORT: 16.92
Ranked among companies with meaningful PE Ratio only.
PE Ratio range over the past 10 years
Min: 9.77, Med: 53.3, Max: 601
Current: 16.92
9.77
601
Forward PE Ratio 12.33
Forward P/E ranked higher than
84.42% of 77 companies
in the Biotechnology industry.
Industry Max: 769.23, Med: 28.41, Min: 3.89
CORT: 12.33
Ranked among companies with meaningful Forward P/E only.
N/A
PE Ratio without NRI 16.92
PE without NRI ranked higher than
83.95% of 243 companies
in the Biotechnology industry.
Industry Max: 5600, Med: 28.64, Min: 0.01
CORT: 16.92
Ranked among companies with meaningful PE without NRI only.
PE without NRI range over the past 10 years
Min: 9.77, Med: 53.3, Max: 601
Current: 16.92
9.77
601
Price-to-Owner-Earnings 15.66
Price-to-Owner-Earnings ranked higher than
85.52% of 145 companies
in the Biotechnology industry.
Industry Max: 305714.29, Med: 34.35, Min: 0.21
CORT: 15.66
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 8.39, Med: 47.8, Max: 667.78
Current: 15.66
8.39
667.78
PB Ratio 4.48
PB Ratio ranked lower than
66.01% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
CORT: 4.48
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 1.82, Med: 16.29, Max: 86.18
Current: 4.48
1.82
86.18
PS Ratio 5.05
PS Ratio ranked higher than
60.06% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
CORT: 5.05
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 4.96, Med: 27.21, Max: 1990
Current: 5.05
4.96
1990
Price-to-Free-Cash-Flow 12.43
Price-to-Free-Cash-Flow ranked higher than
71.05% of 152 companies
in the Biotechnology industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
CORT: 12.43
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 11.01, Med: 43.73, Max: 195.93
Current: 12.43
11.01
195.93
Price-to-Operating-Cash-Flow 12.37
Price-to-Operating-Cash-Flow ranked higher than
64.29% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
CORT: 12.37
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 10.97, Med: 43.46, Max: 188.93
Current: 12.37
10.97
188.93
EV-to-EBIT 11.39
EV-to-EBIT ranked higher than
55.94% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
CORT: 11.39
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -164.1, Med: -4.2, Max: 488.9
Current: 11.39
-164.1
488.9
EV-to-EBITDA 11.30
EV-to-EBITDA ranked higher than
51.96% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
CORT: 11.3
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -171.8, Med: -4.2, Max: 436.4
Current: 11.3
-171.8
436.4
EV-to-Revenue 3.86
EV-to-Revenue ranked higher than
68.09% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
CORT: 3.86
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 4.2, Med: 22.2, Max: 1373.5
Current: 3.86
4.2
1373.5
Current Ratio 6.34
Current Ratio ranked higher than
63.13% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
CORT: 6.34
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.89, Med: 6.51, Max: 37.77
Current: 6.34
1.89
37.77
Quick Ratio 6.19
Quick Ratio ranked higher than
63.22% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
CORT: 6.19
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.81, Med: 6.41, Max: 37.77
Current: 6.19
1.81
37.77
Days Inventory 344.43
Days Inventory ranked lower than
87.53% of 481 companies
in the Biotechnology industry.
Industry Max: 908.49, Med: 125.55, Min: 0.02
CORT: 344.43
Ranked among companies with meaningful Days Inventory only.
Days Inventory range over the past 10 years
Min: 325.74, Med: 387.39, Max: 2487.36
Current: 344.43
325.74
2487.36
Days Sales Outstanding 27.14
Days Sales Outstanding ranked higher than
65.12% of 668 companies
in the Biotechnology industry.
Industry Max: 1096.56, Med: 64.17, Min: 0.06
CORT: 27.14
Ranked among companies with meaningful Days Sales Outstanding only.
Days Sales Outstanding range over the past 10 years
Min: 25.55, Med: 45.16, Max: 61.48
Current: 27.14
25.55
61.48
Days Payable 644.85
Days Payable ranked higher than
93.47% of 536 companies
in the Biotechnology industry.
Industry Max: 1651.36, Med: 63.91, Min: 0.12
CORT: 644.85
Ranked among companies with meaningful Days Payable only.
Days Payable range over the past 10 years
Min: 355.35, Med: 780.49, Max: 15257.8
Current: 644.85
355.35
15257.8

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -4.90
3-Year Share Buyback Rate ranked higher than
78.88% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
CORT: -4.9
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -61.6, Med: -19.9, Max: -3.2
Current: -4.9
-61.6
-3.2

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 4.46
Price-to-Tangible-Book ranked lower than
58.05% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
CORT: 4.46
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 2.31, Med: 6.86, Max: 82.35
Current: 4.46
2.31
82.35
Price-to-Projected-FCF 1.99
Price-to-Intrinsic-Value-Projected-FCF ranked lower than
66.32% of 193 companies
in the Biotechnology industry.
Industry Max: 117, Med: 3.12, Min: 0.09
CORT: 1.99
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
Price-to-Intrinsic-Value-Projected-FCF range over the past 10 years
Min: 1.96, Med: 5.1, Max: 18.81
Current: 1.99
1.96
18.81
Price-to-Median-PS-Value 0.18
Price-to-Median-PS-Value ranked higher than
92.92% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
CORT: 0.18
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.18, Med: 0.9, Max: 43
Current: 0.18
0.18
43
Price-to-Graham-Number 1.83
Price-to-Graham-Number ranked higher than
64.50% of 200 companies
in the Biotechnology industry.
Industry Max: 68.46, Med: 2.27, Min: 0.02
CORT: 1.83
Ranked among companies with meaningful Price-to-Graham-Number only.
Price-to-Graham-Number range over the past 10 years
Min: 1.8, Med: 5.1, Max: 23.74
Current: 1.83
1.8
23.74
Earnings Yield (Joel Greenblatt) % 8.80
Earnings Yield (Greenblatt) ranked higher than
89.45% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
CORT: 8.8
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -110.2, Med: -11.1, Max: 8.96
Current: 8.8
-110.2
8.96

More Statistics

Revenue (TTM) (Mil) $ 258.42
EPS (TTM) $ 0.61
Beta 1.28
Volatility % 45.79
52-Week Range $ 9.14 - 20
Shares Outstanding (Mil) 114.86

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N